Is ALMS a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Alumis (ALMS) rests on Envudeucitinib psoriasis approval path: The lead asset delivered strong Phase 3 skin-clearance results in plaque psoriasis, and management has guided to an NDA filing in the second half of 2026. Product revenue (TTM) is ~$0 (clinical-stage, no approved products). If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. Whether ALMS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company developing oral, precision-designed therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (formerly ESK-001), is an allosteric TYK2 inhibitor that posted positive Phase 3 ONWARD1 and ONWARD2 topline results in moderate-to-severe plaque psoriasis (roughly 65% PASI 90 and over 40% PASI 100 at week 24), with an NDA submission planned for the second half of 2026. The pipeline also includes envudeucitinib in a Phase 2b lupus (SLE) trial, A-005 (a CNS-penetrant TYK2 inhibitor aimed at multiple sclerosis), and lonigutamab (an anti-IGF-1R antibody for thyroid eye disease) that came in through the 2025 merger with ACELYRIN. Because Alumis has no approved products, it generates essentially no product revenue and runs at a large operating loss funded by cash on hand. The all-stock ACELYRIN merger and a January 2026 equity offering (roughly $345 million gross at $17.00 per share) shored up the balance sheet, giving the combined company runway to advance its programs through multiple planned data readouts. The investment picture is therefore binary in character: success at the FDA and in a competitive TYK2 market could re-rate the stock, while a clinical or regulatory setback could sharply reduce it.
What's the case for buying ALMS?
1. Envudeucitinib psoriasis approval path
The lead asset delivered strong Phase 3 skin-clearance results in plaque psoriasis, and management has guided to an NDA filing in the second half of 2026. Approval and a differentiated safety and efficacy label would be the single biggest driver of the company's value.
2. Pipeline expansion beyond psoriasis
Alumis is testing envudeucitinib in systemic lupus (a Phase 2b readout expected in 2026) and is advancing A-005, a brain-penetrant TYK2 inhibitor for multiple sclerosis. Additional positive readouts would broaden the addressable market and reduce single-asset dependence.
3. Balance sheet and cash runway
The ACELYRIN merger plus the January 2026 raise (about $345 million gross) extended the company's runway across several planned catalysts. A funded balance sheet lowers near-term dilution pressure and buys time to reach approval-stage milestones.
4. Oral convenience versus injectable biologics
As an oral therapy, envudeucitinib competes on convenience against injectable IL-23 and IL-17 biologics that dominate psoriasis. If it pairs biologic-like efficacy with pill dosing, that positioning could support commercial adoption after any approval.
What are the risks to ALMS?
As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech.
How is ALMS valued? (as of JULY 2026)
Snapshot for ALMS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Product revenue (TTM): ~$0 (clinical-stage, no approved products)
- Market cap: ~$2.9B
- Pro forma cash (post-merger): ~$737M as of Dec 31, 2024
- January 2026 equity raise: ~$345M gross ($17.00/share)
- Cash runway: into 2027
- Lead asset milestone: psoriasis NDA planned 2H 2026
Alumis cannot be valued on earnings because it has no meaningful revenue and operates at a loss, so the market prices it on the probability-weighted value of its pipeline, chiefly envudeucitinib. The reported market cap reflects investor expectations for approval and launch rather than current cash flow. Balance-sheet strength from the merger and the 2026 raise matters here because runway determines how many catalysts the company can reach before needing more capital.
How do you decide if ALMS is a buy?
Rather than asking whether ALMS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALMS indirectly through an index or sector ETF before adding more.
For the full picture, see the ALMS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALMS against your real portfolio and see your actual exposure before deciding.
The bottom line on ALMS
The bottom line: Alumis's story right now is Envudeucitinib psoriasis approval path, with product revenue (ttm) at ~$0 (clinical-stage, no approved products). If you believe that narrative continues, the call is about sizing ALMS sensibly and checking overlap with what you own; if you doubt it (the risk: as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around ALMS with Walnut
Use Alumis as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ALMS a good stock to buy right now?
+
The case for Alumis right now is Envudeucitinib psoriasis approval path, with product revenue (ttm) at ~$0 (clinical-stage, no approved products). If you believe that thesis holds, ALMS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is as a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Alumis do?
+
Alumis Inc.
What are the main risks of ALMS?
+
As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech.
What does Alumis (ALMS) do?
+
Alumis is a clinical-stage biopharmaceutical company developing oral, precision-designed therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (ESK-001), is an oral TYK2 inhibitor being developed for plaque psoriasis and other autoimmune conditions.
Does Alumis have any approved products or revenue?
+
No. As of mid-2026 Alumis is clinical-stage with no FDA-approved products, so it generates essentially no product revenue and funds operations from cash on its balance sheet. Its value rests on the potential of its pipeline rather than current sales.
What is envudeucitinib (ESK-001)?
+
Envudeucitinib, formerly called ESK-001, is Alumis's lead oral allosteric TYK2 inhibitor. It posted positive Phase 3 ONWARD1 and ONWARD2 results in moderate-to-severe plaque psoriasis (roughly 65% PASI 90 and over 40% PASI 100 at week 24), with an NDA planned for the second half of 2026.
Who does Alumis compete with?
+
Its most direct competitor is Bristol Myers Squibb's Sotyktu (deucravacitinib), the first approved oral TYK2 inhibitor. It also competes against injectable IL-23 and IL-17 psoriasis biologics from AbbVie, Johnson & Johnson, and Novartis, plus other TYK2 programs in development.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ALMS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.